Johnson & Johnson

NYSE: JNJ
$162.76
+$0.17 (+0.1%)
Closing price February 25, 2021
24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week, including Apple, Boeing, Microsoft and Verizon.
While positive earnings could continue to drive the major indexes higher in 2021, a very overbought and fully valued market could offer some painful January indigestion. These five stocks look like...
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Health care is one sector that continues to draw a ton of fund manager interest, and with good reason. These five dividend-paying health care stocks are all favored by large-cap portfolio managers.
Johnson & Johnson released better than expected quarterly results before the markets opened on Tuesday, but it also announced a pause in its late-stage coronavirus vaccine trial.
A new earnings reporting season kicks off this week, with the big banks and a few other companies leading the way. These results will be an important barometer for what comes next.
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.